Welcome to our dedicated page for Bolt Biotherapeutics SEC filings (Ticker: BOLT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, sourced in real time from the U.S. Securities and Exchange Commission’s EDGAR system. As a clinical-stage biopharmaceutical company developing immunotherapies for cancer, Bolt Biotherapeutics uses its SEC filings to report financial results, material corporate events, and updates on its research and development activities.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q to understand the company’s research and development spending, collaboration revenue from its partnerships, and detailed risk factors related to advancing product candidates such as BDC-3042 and BDC-4182. These filings also describe the Boltbody ISAC platform, the status of clinical and preclinical programs, and the company’s cash position and operating runway as disclosed in its financial statements.
Current reports on Form 8-K provide timely information about specific events, such as announcements of quarterly financial results, restructuring plans that include workforce reductions, and updates on ongoing clinical studies. For example, Bolt Biotherapeutics has used Form 8-K to furnish press releases describing changes to the BDC-4182 Phase 1 protocol and the expected timing of initial clinical data, as well as to outline cost-reduction measures intended to preserve cash.
Through this page, users can also access insider transaction reports on Form 4 and other relevant filings, when available, to monitor equity transactions by officers and directors. Stock Titan’s interface is designed to pair these documents with AI-powered summaries that explain key points in accessible language, helping readers quickly interpret complex disclosures without replacing the underlying source documents. By reviewing Bolt Biotherapeutics’ SEC filings alongside news and market data, investors can form a more complete picture of the company’s financial condition, pipeline progress, and regulatory communications.
Bolt Biotherapeutics files its annual report outlining a focused immuno-oncology strategy built around its Boltbody ISAC platform. The company is prioritizing clinical development of BDC-4182, a claudin 18.2-targeting ISAC in a first-in-human Phase 1 trial for gastric/gastroesophageal junction cancer, while other pipeline programs are on hold pending funding or partnerships.
Bolt highlights collaborations with Toray, Genmab and Innovent, an exclusive license to core ISAC technology from Stanford, and a patent estate expected to run into the 2040s. As of June 30, 2025, non-affiliate common stock held a market value of about $7.3 million, and as of March 6, 2026, 1,921,567 shares of common stock were outstanding. The company reports only 23 employees and emphasizes that it has a limited operating history, significant accumulated losses, substantial future funding needs, and numerous clinical, regulatory, manufacturing, competition, reimbursement and macroeconomic risks that could affect its ability to commercialize any product candidates and maintain its stock price.
Bolt Biotherapeutics reported fourth-quarter and full-year 2025 results showing sharply lower operating losses and a more focused pipeline. Full-year loss from operations narrowed to
Collaboration revenue was
The lead Boltbody™ ISAC candidate, BDC-4182 targeting claudin 18.2, is in a Phase 1 dose-escalation trial in gastric and gastroesophageal cancers, with initial clinical data expected in the third quarter of
Bolt Biotherapeutics, Inc. received an amended Schedule 13D showing updated ownership by Nan Fung- and Pivotal-affiliated entities in its common stock. Nan Fung Group Holdings Limited reports beneficial ownership of 87,486 shares, or 4.6% of the common stock, with other related entities holding smaller stakes.
The reported percentages are calculated using 1,919,441 outstanding shares of common stock, as referenced from the company’s Form 10-Q filed on November 12, 2025. The filing states that on February 26, 2026, the reporting persons ceased to be beneficial owners of more than five percent of Bolt’s common stock. In addition, Mr. Kam Chung Leung directly owns 8,684 shares of common stock.
Nal Fung–affiliated and Pivotal bioVenture entities filed Amendment No. 3 to report their beneficial ownership of Bolt Biotherapeutics common stock. Nan Fung Group Holdings Limited reports beneficial ownership of 128,119 shares, representing 6.7% of the common stock.
Several related entities, including Pivotal bioVenture Partners Fund I, L.P., report shared voting and dispositive power over 78,445 shares, or 4.1% of the class, while other Nan Fung life sciences entities report additional stakes ranging from 0.3% to 6.4%. The percentages are calculated against 1,919,441 shares outstanding as of the issuer’s Form 10‑Q filed November 12, 2025. The filing also notes that Mr. Kam Chung Leung directly owns 8,684 shares and that, except as described in an attached schedule, no reporting person has traded the stock in the past sixty days.
Vivo Panda Fund, L.P., an investor in Bolt Biotherapeutics, Inc., reports beneficial ownership of 72,414 shares of Bolt common stock, representing 3.8% of the class, in this amended Schedule 13G. The percentage is based on 1,919,441 shares outstanding as of November 5, 2025, as disclosed in Bolt’s Form 10-Q. Other affiliated Vivo Capital funds now report 0 shares and 0% ownership. The filers certify the shares are not held to change or influence control of Bolt.
Bolt Biotherapeutics President, CEO and CFO William P. Quinn reported two transactions in company securities. On December 5, 2025, he purchased 125 shares of common stock at
On January 28, 2026, he was granted an employee stock option for 20,000 shares of common stock at an exercise price of
Bolt Biotherapeutics, Inc. reported that its Chief Operating Officer, Yonehiro Grant, received an employee stock option grant. On January 28, 2026, Grant was awarded options to purchase 10,000 shares of Bolt common stock at an exercise price of $6.71 per share, expiring January 27, 2036.
The options vest over time, so long as Grant continues providing services to Bolt. Starting from January 1, 2026, 1/36 of the options vest after each completed month of continuous service, until all 10,000 options are fully vested.
Bolt Biotherapeutics officer reports small share purchase and new option grant. Senior VP, Finance and PAO Sarah Nemec bought 125 shares of common stock on 12/05/2025 at $4.607 per share under the company’s Employee Stock Purchase Plan, bringing her direct holdings to 1,415 shares.
On 01/28/2026 she received an employee stock option for 8,000 shares at a $6.71 exercise price. This option is scheduled to vest in equal monthly installments, with 1/36 of the shares vesting after each month of continuous service following January 1, 2026, and expires on January 27, 2036.
A director of Bolt Biotherapeutics, Inc. reported cancelling previously granted director stock options and receiving new options with lower exercise prices.
On December 12, 2025, the director received new options to buy 2,500, 849, 1,000 and 1,100 shares of common stock at an exercise price of $5.44 per share, with expiration dates between September 2, 2034 and May 26, 2035. In each case, options with higher exercise prices ranging from $6.40 to $13.596 for the same number of shares and similar expiration dates were cancelled in exchange for the new options, some of which are fully vested and others subject to monthly or time-based vesting and full vesting upon a change in control.
Bolt Biotherapeutics, Inc. director reported stock option transactions dated
New director stock options with exercise prices such as